Wave Life Sciences Ltd (NASDAQ:WVE) has received an average recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $45.00.
A number of equities analysts have commented on the company. ValuEngine raised Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 29th. Guggenheim began coverage on Wave Life Sciences in a research note on Friday, November 1st. They issued a “buy” rating and a $43.00 price objective for the company. BidaskClub raised Wave Life Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Mizuho started coverage on shares of Wave Life Sciences in a report on Thursday, November 21st. They issued a “buy” rating and a $65.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th.
In other news, Director Gregory L. Verdine sold 30,039 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.63, for a total transaction of $920,094.57. Following the transaction, the director now owns 36,009 shares of the company’s stock, valued at approximately $1,102,955.67. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 39.70% of the stock is owned by company insiders.
Shares of WVE stock traded down $0.13 on Tuesday, reaching $34.10. 365,843 shares of the company were exchanged, compared to its average volume of 328,216. Wave Life Sciences has a 1 year low of $17.59 and a 1 year high of $50.98. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.88 and a current ratio of 1.88. The business has a 50-day moving average price of $26.70 and a 200 day moving average price of $24.12. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -6.77 and a beta of 0.91.
Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. The firm had revenue of $2.93 million during the quarter, compared to analyst estimates of $6.30 million. As a group, equities analysts anticipate that Wave Life Sciences will post -5.54 earnings per share for the current year.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Featured Story: Why do company’s buyback their stock?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.